Clinical Trials Browser

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Hypertension, Kidney Diseases, Prostatic Neoplasms, Primary Dysautonomias

Prostatic Neoplasms

Neoplasm Metastasis, Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Neoplasm Metastasis, Prostatic Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Neoplasm Metastasis, Prostatic Neoplasms

Prostatic Neoplasms

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Neoplasm Metastasis, Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Colorectal Neoplasms

Prostatic Neoplasms

Breast Neoplasms, Prostatic Neoplasms

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Prostatic Neoplasms

Clinical Trials

Radium-223 in Combination With Enzalutamide

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

ARCH

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

PROSPER

CheckMate 9KD

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)

Testosterone Therapy in Castration Resistant Prostate Cancer

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

ARROW

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely

Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

KEYLYNK-010

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

ZZ-First

Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer

PRESIDE

Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

ENACT

Micro RNAs to Predict Response to Androgen Deprivation Therapy

A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients

A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer

Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.

PREMISE

Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

BonEnza

CHEIRON

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer

PLATO

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC

Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer